Osilodrostat

Drug Profile

Osilodrostat

Alternative Names: LCI-699

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Fluorobenzenes; Imidazoles; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pituitary ACTH hypersecretion
  • Phase II Cushing syndrome
  • Discontinued Heart failure; Hypertension; Solid tumours

Most Recent Events

  • 01 Apr 2017 Efficacy and adverse events data from phase II trials in Cushing's syndrome presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 15 Dec 2016 Biomarkers information updated
  • 29 Apr 2016 Phase-III clinical trials in Pituitary ACTH hypersecretion in Greece, Belgium (PO) (EudraCT2014-004092-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top